## FORM 4

obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Reis James Richard</u>						2. Issuer Name and Ticker or Trading Symbol Arcadia Biosciences, Inc. [ RKDA ]										5. Relationship of Repor (Check all applicable) X Director			porting Person(s) to Issuer 10% Owner	
(Last) 3333 LE	Last) (First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 07/09/2016											Office below	r (give title )		Other (s below)	specify
(Street)  DALLAS  (City)	ALLAS TX 75219				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									Line	6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Tab	le I - Non	-Deriv	ative	Se	curiti	es A	cqu	ired,	Disp	osed o	of, or	Bene	eficial	ly Owne	d			
1. Title of Security (Instr. 3)  2. Transa Date (Month/D					saction	ar)	2A. Deemed Execution Date, if any (Month/Day/Year		е,	3. Transactio Code (Inst		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)		(A) or	5. Amor Securit Benefic Owned	unt of es ially Following	Forn (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
										Code	v	Amount	(4	A) or O)	Price	Reporte Transac (Instr. 3	ction(s)			(Instr. 4)
Common Stock																50	50,000		D	
		Т	able II - I									sed of onverti				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemee Execution I if any (Month/Day	Date,	4. Transa Code (I 8)		of		Exp	6. Date Exercisal Expiration Date (Month/Day/Year)			e and 7. Title ai of Securi Underlyi Derivativ (Instr. 3 a		curity	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transactior (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Dat Exe	e ercisable		piration te	Title	OI No Of	umber					
Employee Stock Option (right to buy)	\$2.24									(1)	12/	31/2019	Comm Stock		5,000		15,000	)	D	
Employee Stock Option (right to	\$7.2									(2)	02/	11/2015	Comm Stock		5,000		5,000		D	

## **Explanation of Responses:**

buy)

1. The Reporting Person resigned his position as a Director of Arcadia Biosciences, Inc. (the "Issuer") effective July 9, 2016 (the "Resignation Date"). As of the Resignation Date, the Reporting Person is no longer subject to Section 16 in connection with his transactions in the Issuer's equity securities and therefore will report only non-exempt transactions occurring within six months of opposite-way non-exempt transactions on future Forms 4 and 5. As of the Resignation Date, there were a total of 15,000 shares vested and exercisable pursuant to the Issuer's 2006 Stock Plan and the applicable Stock Option Award Agreement. The vested options will remain exercisable for a period of thirty (30) days following the Resignation Date.

2. As of the Resignation Date (as defined in Footnote 1), there were a total of 5,000 shares vested and exercisable pursuant to the Issuer's 2006 Stock Plan and the applicable Stock Option Award Agreement. The vested options will remain exercisable for a period of thirty (30) days following the Resignation Date.

> /s/ James R. Reis 07/20/2016

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.